Motor neurone disease systematic multi-arm adaptive randomised trial (MND-SMART)

UK Chief Investigator

Professor Siddharthan Chandran

Research summary

MND-SMART stands for Motor Neuron Disease – Systematic Multi-arm Adaptive Randomised Trial. 

Multi-arm means that, unlike typical clinical trials which test a single treatment, MND-SMART will test more than one at the same time. Trial participants taking the different treatments will be compared with a single group who receive a dummy drug, called a placebo. This means that people in MND-SMART are more likely to receive an active treatment when compared to standard clinical trials where half of participants receive the placebo and half the active treatment.

The trial is also adaptive so that researchers can change the drugs being tested according to emerging results. This means that new medicines can be added once a trial has started, while treatments that do not prove effective can be dropped. This is a phase 2 / 3 trial which means if drugs appear to be effective, they will seamlessly transition into phase 3 without the need for additional permissions or trial participants needing to complete a phase 2 trial and join a separate phase 3 trial. 

Current status

Open to recruitment

Recruitment target

Up to 800 participants

Click here to see how many patients have been recruited into this study to date (external link to the NIHR public study search) 

Recruitment group(s)

Patients with MND





Northern Ireland:

Information about study sites

Contact details



Telephone: 0131 242 9122

Key dates

Recruitment open date: 20 February 2020

Planned recruitment end date: 02 November 2026

Inclusion / exclusion criteria

Inclusion criteria

Exclusion criteria



NHS Lothian

Study design

Interventional; multi-arm, multi-stage, adaptive, randomised controlled trial

Current interventions



Outcome measures

Co-primary outcome measures

Secondary outcomes